Company: LNAI
Filing Date: 2025-03-06
Form Type: 425
Source: 0001731122-25-000356
Chunk: 2

Company: Lunai Bioworks Inc.
Filing Date: 2025-03-06
Form: 425
Chunk 2
---
 securities of Renovaro to be issued in the proposed transaction. The information in the preliminary proxy
statement/prospectus will not be complete and may be changed. Predictive Oncology will deliver the definitive proxy statement to its stockholders
as required by applicable law. This communication is not a substitute for any prospectus, proxy statement or any other document that may
be filed with the SEC in connection with the proposed business combination.

INVESTORS AND SECURITY HOLDERS
ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT/PROSPECTUS AND OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN
THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION.

Investors and security holders
will be able to obtain these materials (when they are available) and other documents filed with the SEC free of charge at the SEC’s
website, www.sec.gov. Copies of documents filed with the SEC by Renovaro (when they become available) may be obtained free of charge
at Renovaro’s website at renovarogroup.com. Copies of documents filed with the SEC by Predictive Oncology (when they become available)
may be obtained free of charge on Predictive Oncology’s website at predictive-oncology.com.

Participants in the Solicitation:

Predictive Oncology and its directors,
executive officers and certain other members of management and employees may be deemed to be participants in the solicitation of proxies
in respect of the proposed transaction. Information regarding these persons who may, under the rules of the SEC, be considered participants
in the solicitation of Predictive Oncology stockholders in connection with the proposed transaction and their interests in the transaction
will be set forth in the proxy statement/prospectus described above filed with the SEC. Additional information regarding Predictive Oncology’s
executive officers and directors is included in Predictive Oncology’s annual report on Form 10-K for the year ended December 31,
2023 filed with the SEC on March 28, 2024 and Predictive Oncology’s proxy statement for its 2024 annual meeting of stockholders
filed with the SEC on November 27, 2024. These documents may be obtained free of charge at the SEC’s website, www.sec.gov, or Predictive
Oncology’s website, predictive-oncology.com.

Forward-Looking Statements

This Current Report on Form 8-K
includes forward-looking statements within the